gwt1

APX2039 is an orally active fungal Gwt1 enzyme inhibitor and a prodrug of the novel Gwt2096 inhibitor APX1.APX2039 exhibits potent anti-Kryptococcal activity against C. neoformans and C. gattii.APX2039 exhibits potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol) anchored cell wall mannoproteins. APX2039 has potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol)-anchored cell wall mannoproteins.APX2039 can be used to study cryptococcal meningitis (CM).

APX001 is a prodrug of APX-001A. APX001 is the first-in-class inhibitor of the fungal protein Gwt1.

Fosmanogepix (APX001) is a first-in-class, orally available broad-spectrum antifungal agent. It acts as an N-phosphonooxymethyl prodrug that undergoes rapid and complete metabolism by systemic alkaline phosphatases. This metabolism leads to the formation of the active moiety, APX001A. Fosmanogepix (APX001), with its ability to target the highly conserved Gwt1 fungal enzyme, holds great potential for the development of treatments against invasive fungal infections.